Correction: Benefits of Aldosterone Receptor Antagonism in Chronic Kidney Disease (BARACK D) trial-a multi-centre, prospective, randomised, open, blinded end-point, 36-month study of 2,616 patients within primary care with stage 3b chronic kidney disease to compare the efficacy of spironolactone 25 mg once daily in addition to routine care on mortality and cardiovascular outcomes versus routine care alone: study protocol for a randomized controlled trial.
Hill, Nathan R Lasserson, Daniel Thompson, Ben Perera-Salazar, Rafael Wolstenholme, Jane Bower, Peter Blakeman, Thomas Fitzmaurice, David Little, Paul Feder, Gene
Hill, Nathan R
Lasserson, Daniel
Thompson, Ben
Perera-Salazar, Rafael
Wolstenholme, Jane
Bower, Peter
Blakeman, Thomas
Fitzmaurice, David
Little, Paul
Feder, Gene
Citations
Altmetric:
Affiliation
Other Contributors
Publication date
2022-12-12
Subject
Collections
Research Projects
Organizational Units
Journal Issue
Abstract
None available
Citation
Hill NR, Lasserson D, Thompson B, Perera-Salazar R, Wolstenholme J, Bower P, Blakeman T, Fitzmaurice D, Little P, Feder G, Qureshi N, Taal M, Townend J, Ferro C, McManus R, Hobbs FDR. Correction: Benefits of Aldosterone Receptor Antagonism in Chronic Kidney Disease (BARACK D) trial-a multi-centre, prospective, randomised, open, blinded end-point, 36-month study of 2,616 patients within primary care with stage 3b chronic kidney disease to compare the efficacy of spironolactone 25 mg once daily in addition to routine care on mortality and cardiovascular outcomes versus routine care alone: study protocol for a randomized controlled trial. Trials. 2022 Dec 12;23(1):999. doi: 10.1186/s13063-022-06972-9. Erratum for: Trials. 2014 May 08;15:160.
Type
Corrigendum